The Cooper Companies’ shares fell $9.31, or 14.6%, on Sept. 10, 2026, after the medical-device maker reported third-quarter results that disclosed U.S. channel inventory destocking and other negative developments. The decline erased more than $1.7 billion in market capitalization and took the stock to a 52-week closing low of $54.17. Hagens Berman has opened an investigation into whether Cooper was sufficiently transparent about the sales practices behind CooperVision’s revenue growth and whether any lack of disclosure violated securities laws. CooperVision generated roughly 67% of Cooper’s consolidated sales in fiscal 2025. The firm is seeking information from investors with substantial losses and people with relevant non-public information, including potential SEC whistleblowers. The SEC program provides for awards of up to 30% of a successful recovery for eligible original information.